Proteomics International Develops Process to ID Venom Peptides for Drug Development | GenomeWeb

This story was originally published on May 6.

Spiders, snakes, and centipedes may be the stuff nightmares are made of, but for one Australian firm they may form the foundation for its future.

Last month, Proteomics International announced the development of Bioven, a process that links mass spectrometry with proprietary algorithms to determine peptide identify and predict their functions. Using this process, the company said that up to five times as many potential drug candidates can be recovered from venom than had been previously achieved.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.